UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF
REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13
AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number
001-33882
Cascadian Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
3101 Western Avenue, Suite 600
Seattle, Washington 98121
(206)801-2100
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule12g-4(a)(1) | ☒ | |
Rule12g-4(a)(2) | ☐ | |
Rule12h-3(b)(1)(i) | ☒ | |
Rule12h-3(b)(1)(ii) | ☐ | |
Rule15d-6 | ☐ | |
Rule15d-22(d) | ☐ |
Approximate number of holders of record as of the certification or notice date: 1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this certification/notice to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 22, 2018
| Cascadian Therapeutics, Inc. | ||||
| By: | /s/ Venkat Ramanan | |||
| Name: | Venkat Ramanan | |||
| Title: | Vice President, Finance | |||
